Hematologic Malignancies

Transcription

1 C O N N E C T I N G L I F E A N D S C I E N C E Hematologic Malignancies Issue Number 7 Spring 2010 Myelodysplastic Syndromes Peter Westervelt, M.D., Ph.D., Associate Professor of Medicine Chief, Section of Bone Marrow Transplantation, Washington University School of Medicine Myelodysplastic syndromes (MDS) represent a related group of bone marrow disorders that share features of bone marrow failure and, to a variable degree, a predisposition toward progression to acute myelogenous leukemia (AML). Reflective of these dual manifestations, goals of treatment for MDS include both the amelioration of cytopenias and delaying the progression to acute leukemia. In addition to disease-focused treatment measures, supportive care remains an important component in the management of patients with MDS. Allogeneic stem cell transplantation, the only potentially curative treatment option for MDS, should be considered for younger patients with available donors, however, appropriate timing of transplant is important to minimize exposing patients with low risk disease to unnecessary risk early in the course of their disease. This overview of the management of MDS will attempt to address and provide our institutional perspectives on these current issues in the management of MDS. Treatment of MDS Until the last decade, supportive measures represented the standard of care for patients with MDS. Numerous studies of chemotherapy regimens developed for treating AML have failed to show convincing evidence of benefit in MDS patients, due in part to suboptimal complete response rates and poor tolerance by typically older MDS patient populations. Within the past 10 years, however, three drugs have been approved by the FDA for the treatment of MDS. Two of these agents, azacytidine and To refer a patient, please call: Call Monday-Friday 8:30 a.m. to 4:30 p.m. central time. Within 24 hours (excluding weekend and holidays) a new patient coordinator will contact your office to facilitate the referral process. If a patient requires direct admission or emergent transfer, please call Available 24 hours a day, seven days a week. decitabine, are structurally similar and are believed to function by inhibiting the enzyme DNA methyltransferase, responsible for silencing the expression of tumor suppressor genes that are postulated to play a role the pathogenesis of MDS. Both azacytidine and decitabine produce complete or nearcomplete response rates of approximately 20-25%, and overall response rates of ~50% (including hematologic improvement). In addition, both agents have been shown in randomized trials to delay the progression to AML, and azacytidine has resulted in prolonged overall survival compared with supportive care alone, low dose cytarabine, or standard anti-leukemic induction chemotherapy. Although originally approved based on a threetimes-daily dosing regimen (15 mg/ m2 q8 hours for 3 days), decitabine is more commonly administered as a daily regimen associated with less myelosupression and better suited to outpatient administration (20 mg/m2 daily for 5 days). Based on their acceptably modest toxicities (primarily mild myelosuppression), outside of a clinical trial it is reasonable to offer a trial of a hypomethylating agent to most patients with higher risk (as defined by IPSS score) or transfusion-dependent MDS. The optimal duration of therapy for responding patients is not well-defined. In published studies utilizing these agents, responding patients continued therapy until progression, although there is no evidence that observation after a prolonged course of therapy, for example in patients achieving a complete response, might not result in equivalent outcomes. The benefit of treating (continued on page 2)

2 Hematologic Malignancies asymptomatic, non-transfusion-dependent patients with low risk disease has not been established and these patients should generally be observed without treatment until symptomatic disease progression. Lenalidomide, an orally bioavailable thalidomide analog originally developed and approved as a treatment for multiple myeloma, is highly active in treating the subset of MDS patients with 5Q minus syndrome. Treatment of red blood cell transfusion-dependent 5Q minus syndrome patients with lenalidomide has been shown to eliminate the need for transfusional support in 76% of patients, usually within a few weeks of initiating treatment, with most responses persisting for over two years. Although responses were seen across a spectrum of additional karyotypic abnormalities seen in conjunction with the 5Q minus deletion, responses in the absence of a 5Q deletion have been relatively modest (25% hematologic improvement). Hence, a trial of lenalidomide should be considered frontline therapy only for those patients with a 5Q deletion. We are currently investigating the use of decitabine in combination with an investigational oral histone deacetylase inhibitor (LBH589). Eligibility requirements for this study include age greater than 60, advanced MDS with an IPSS score 1.5 or greater, and no prior treatment with azacytidine or decitabine. This study is also open to patients over age 60 with AML. Allogeneic stem cell transplantation Whereas stem cell transplantation was once reserved for the relatively small subset of MDS patients under age 60 in good overall health, it is no longer unusual for selected patients well into their 60 s (or older) to undergo allogeneic stem cell transplantation utilizing reduced intensity conditioning regimens. Determining the optimal timing of stem cell transplantation for MDS can challenging, balancing its substantial treatmentrelated toxicity with better transplant outcomes when deployed earlier in the course of the disease. In general, however, it is reasonable to delay transplant in low risk patients until progression (transfusion dependence, increasing blasts, eg), and to transplant upfront in patients with more advanced disease. This approach has been validated by a study based on retrospective outcomes analysis of three large registries of MDS patients. The role of induction therapy prior to transplant is poorly defined. Most studies have demonstrated minimal benefit for AML induction chemotherapy prior to transplant for MDS, despite evidence that patients in remission at transplant fare better overall. There is, moreover, no clear evidence that less aggressive treatment with a hypomethylating agent prior to transplant improves transplant outcome, albeit based only on retrospective analysis of a small series of patients. Decisions regarding treatment of MDS patients where the goal is to establish a bridge to transplant are individualized, and typically influenced by factors such as donor availability and the pace of disease progression. Recommendations 1. Observation alone in low risk, transfusion-independent MDS patients 2. Therapeutic trial of azacytidine or decitabine higher risk (IPSS > 1.5) or transfusion dependent patients 3. Therapeutic trial of lenalidomide for patients with 5Q minus syndrome 4. Early referral for consideration of allogeneic stem cell transplant 5. Enrollment in well-designed clinical trials whenever possible Save the Date Continuing Medical Education: Advances in Diagnosis and Treatment of Hematologic Malignancies August 28, 2010 at the Four Seasons Hotel in St. Louis, Missouri Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is hosting an educational symposium entitled Advances in Diagnosis and Treatment of Hematologic Malignancies. The symposium will take place on Saturday, August 28 at the Four Seasons Hotel in St. Louis, Missouri. The annual symposium provides the audience with updated information on cancer treatment and diagnosis through discussions on hematological malignancies. In addition to the conference, we are hosting our 17th Annual Bone Marrow Transplant Patient Celebration on Saturday, August 28, in the ballroom of the St. Louis Four Seasons Hotel. You and a guest are invited to attend this event in honor of our survivors. Please join us for a private physician reception an hour prior to the patient celebration. If you are interested in attending the symposium, physician reception or the patient celebration, please call the CME office at Washington University School of Medicine at or

3 Hematological Malignancies is published by The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. The Siteman Cancer Center is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI) and is a member of the National Comprehensive Cancer Center Network (NCCN). Editors: Geoffrey Uy, M.D. and Ryan Monahan Article Contributors: Peter Westervelt M.D., Ph.D. Production Manager: Angela Benassi Clinical Trials To learn more about the clinical Trials, or to enroll a patient, please contact the listed study coordinator at AML, newly diagnosed Acute Leukemia /MDS CALGB PI: Geoffrey Uy A Phase III Randomized, double-blind Study of Induction (Daunorubicin/ Cytarabine and Consolidation (High-dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND#101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia Notes: Newly dx de novo AML age 18-59, decitabine maintenance after induction and risk adapted consolidation based on cytogenetics to either HiDAC or auto transplant- CALGB PI: Geoffrey Uy Phase II Study of Maintenance Therapy With Decitabine Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML 60 Years. Notes: Newly dx de novo AML age 18-59, decitabine maintenance after induction and risk adapted consolidation based on cytogenetics to either HiDAC or auto transplant PI: Geoffrey Uy A Phase I, Dose Escalation Study of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia Notes: Newly dx de novo AML age PI: John DiPersio Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome PI: Geoffrey Uy SWOG S0521 A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III. Notes: Low or intermediate risk APL 18 years and older with no prior systemic therapy or recurrent disease PI: Geoffrey Uy Jeff Demland A Phase I/II Study of LBH589 plus Decitabine for Patients Age > 60 Years with High Risk MDS or AML Notes: Age > 60 with MDS (IPSS 1.5) or AML with no prior treatment with a hypomethylating agent AML, relapsed refractory PI: Geoffrey Uy Jeff Demland A Phase I Study of Intravenous Plerixafor in Combination with Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia Notes: Age with either primary refractory AML, relapsed AML MDS/AML, other PI: Geoffrey Uy Jeff Demland A Phase I/II Study of LBH589 plus Decitabine for Patients Age > 60 Years with High Risk MDS or AML Notes: Age > 60 with MDS (IPSS 1.5) or AML with no prior treatment with a hypomethylating agent PI: Camille Abboud Sarah Witowski Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia Notes AML in CR1, 60 years old,up to one cycle of HiDAC allowed. (continued on page 4) 3

4 Hematologic Malignancies Clinical Trials To learn more about the clinical Trials, or to enroll a patient, please contact the listed study coordinator at PI: John DiPersio PI: Nina Wagner- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome PI: Camille Abboud A Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (saml/mds ALL A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects with Indolent Non-Hodgkin s Lymphoma (NHL) that is Refractory to or has Relapsed after Rituximab and Chemotherapy or Radioimmunotherapy Notes: Patients with Follicular, Marginal Zone, or SLL are eligible; must have progressed after at least 2 prior therapies; Patients must have had no response or have progressed within 6 months from the completion of Rituxan or Rituxan containing therapy or within 12 months of completion of RIT. Large Cell CALGB PI: Geoffrey Uy CALGB PI: Nancy L. An Intergroup Phase II Clinical Trial for Adolescents and Young adults with Untreated Acute Lymphoblastic Leukemia. Notes: Newly diagnosed and untreated ALL between the age of 16 and 40 Indolent NON-HODGKIN LYMPHOMA (NHL) CALGB PI: Nancy L. A Randomized Phase II trial of Rituximab vs. Lenalidomide (RevlimidTM, CC-5013) (IND # 73034) vs. Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That Is Not Rituximab-Refractory (Arm A, Rituximab Alone, was permanently closed effective 9/15/2007) Notes: Patients must have been treated with rituximab either alone or in combination with chemotherapy. The last prior treatment regimen need not include rituximab but must have progressed >6 months from their last rituximab dose PI: Nancy L. A Phase I/II Dose Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI in Lymphoma Notes: Patients must have had no more than 4 prior therapies; prior allogeneic transplant not allowed. Only open for Follicular NHL and Mantle Cell Lymphoma Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Notes: Patients must have a new biopsy if fresh/frozen tissue was not available from their first biopsy, unless contraindicated PI: Nina Wagner- An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/ Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation PI: Nina Wagner- A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy 4

5 Mantle Cell PI: Nancy L. Primary CNS RTOG 0227 PI: David Mansur Shannon Rickey An open-label, Single Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma Notes: Patients must have been refractory to Bortezomib and to their last line of therapy (if other than Bortezomib). CALGB PI: Nancy L. A Randomized Phase II Trial of Maintenance vs. Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma Notes: Patients must be between the ages of 18 and 69 years with any stage (I-IV). CALGB PI: Nancy L. A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid TM, CC-5013) (NSC#703813) For Relapsed/Refractory Mantle Cell Lymphoma Notes: Patients may not have received prior bortezomib or lenalidomide therapy PI: Nancy L PI: Nancy L. A Phase I/II Dose Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI in Lymphoma Notes: Patients must have had no more than 4 prior therapies; prior allogeneic transplant not allowed. Only open for Follicular NHL and Mantle Cell Lymphoma A Phase 2, Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent Lenalidomide (Revlimid) in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. AIDS/HTLV AMC 048 PI: Lee Ratner Lee Ratner Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including Central Nervous System (CNS) Penetration and Intensive Intrathecal (IT) Prophylaxis in HIV-Associated Burkitt s and Atypical Burkitt s Lymphoma. Phase I/II Study of Pre-Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and Post- Irradiation Temozolomide for Primary Central Nervous System Lymphoma All Lymphoma Histologies PI: Nina Wagner- A Phase I Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies. Notes: open to patients with Indolent B-Cell, Mantle Cell, and CLL. T-Cell PI: Nancy L. Pivotal Study of SGN-35 in Treatment of Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL) PI: Nancy L. Retreatment with SGN-35 in Patients with CD30-positive Hematologic Malignancies Notes: For patients who experienced either a complete or partial remission with known SGN-35 treatment, and had relapse after discontinuing treatment in the prior SGN-35 study PI: Nancy L. Treatment of Peripheral T-Cell Lymphoma with Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant using Denileukin Diftitox (Ontak) for in-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial Notes: For patients with previously untreated T-Cell Lymphoma or could have received up to 1 prior cycle of chemotherapy. (continued on page 6) 5

6 Hematologic Malignancies Clinical Trials (continued) HODGKIN LYMPHOMA (HL) Chronic Lymphocytic Leukemia (CLL) SWOG S0816 PI: Nancy L. A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging PI: Nancy L. Retreatment with SGN-35 in Patients with CD30-positive Hematologic Malignancies Notes: For patients who experienced either a complete or partial remission with known SGN-35 treatment, and had relapse after discontinuing treatment in the prior SGN-35 study PI: Nancy L. A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Notes: Patients must have recurred after at least 1 prior therapy. Patients with any stage and who have had prior autologous or allogeneic stem cell transplant are eligible PI: Nancy L. A Randomized Phase II study of Rituximab with ABVD vs. Standard ABVD for Patients with Advanced-Stage Classical Hodgkin Lymphoma with Poor Risk Features Notes: IPS Score > PI: Nancy L. A Phase I/II an Open-Label Study of Pralatrexate and Gemcitabine with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Lymphoproliferative Malignancies Notes: Patients must have at least 1 prior treatment; no prior allogeneic transplant; patients must have relapsed > 100 days from autologous transplant. CALGB PI: Nancy L. A Randomized Phase II Study of Three Fludarabine/ antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia Notes: For previously untreated CLL patients requiring therapy (symptomatic, intermediate or high-risk by Rai staging system). Multiple Myeloma PI: Ravi Vij Mark Fiala A Phase 1b, Multicenter, Open-label, Dose-escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed Multiple Myeloma Notes: Ages 18 and older Lenalidomide naïve with measurable disease and disease progression on their prior line of therapy PI: Ravi Vij Mark Fiala A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone or in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment that Included Lenalidomide and Bortezomib Notes: Relapsed or relapsed/refractory Multiple Myeloma patients 18 years old or greater with measurable disease and at least 2 prior lines of therapy PI: Ravi Vij Mark Fiala Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRD) in Subjects with Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy (MMRC\University of Michigan) Notes: Newly diagnosed stage I, II, or III ages 18 and older with measurable disease. 6

7 General Transplant PI: John DiPersio Sandra Lopez A Phase II Study Evaluating the Safety and Efficacy of Intravenous AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies Notes: Any patient aged with (matched donor 18-70) in first or greater remission with a dx of AML, ALL, high grade MDS, CML in accelerated phase or > 2 remission, Myeloma stage 2-3, NHL or HD in > 2 remission, and CLL Rai Stage 2-4 failing at least 2 prior therapies PI: Amanda Cashen Stefanie Goran A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells Collected From Patients with Lymphoma. Notes: Any patient aged with hodgkins or non-hodgkins lymphoma and eligible for autologous transplant PI: John DiPersio A Multicenter, Prospective Trial to Evaluate the Role of NK Cell Kir Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation from HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies (MT ). CTN 0603 PI: Peter Westervelt Jeremy Gabriel A Multicenter, Phase II Trial of Nonmyeloblative Conditioning (NST)and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies (BMT CTN 0603). Notes: Open to AML in 2nd or subsequent CR or AML in high risk CR1, ALL in high risk CR1, Burkitt s Lymphoma in 2nd or subsequent CR, Lymphoma (large cell, Mantle cell and Hodgkin s in CR or PR and marginal and B-cell lymphoma progressed after 2 or more therapies) PI: John DiPersio Jeremy Gabriel Infusion of Genetically Modified T cells: A Phase I Study of Tracking and Toxicity Notes: Ages > 18, prior recipients of allogeneic BMT for any hematologic malignancy. Eligible patients would include those with leukemia, non Hodgkins Lymphoma, Hodgkins Disease, myelodysplastic syndrome and multiple myeloma PI:Keith Stockerl- Goldstein Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin s Lymphoma Notes: Ages 18-70, must have relapse or persistent disease following allogeneic transplant. GVHD PI: John DiPersio Stefanie Goran A Phase 2, Open-Label, Single Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients with Advanced Chronic Graft-Versus-Host Disease. 7